Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iopofosine I 131 in Relapsed/Refractory B-Cell Malignancies (CLOVER-1 and CLOVER-WaM)
NCT02952508Phase 2Active, not recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Jul 2017
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 11
01
Overview
Phase 2, open-label trial of Iopofosine I-131 in Waldenstrom macroglobulinemia (WM), multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and 6 more (4 arms), sponsored by Cellectar Biosciences. Primary endpoints: Clinical Benefit Rate at 84 days and Major Response Rate at 12 months. Started Jul 2017; status: active, not recruiting.
02
Drugs
Iopofosine I-131
03
Conditions
Waldenstrom macroglobulinemia (WM)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT02952508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952508.